Monthly Archives: February 2020

Bioactive Adrenomedullin, measured with sphingotec’s bio-ADM® assay plays a key role in septic shock patients as top-line results of AdrenOSS-2 Phase II Study indicate

Bioactive Adrenomedullin is a biomarker for endothelial dysfunction and allows the prediction of septic shock as elevated blood levels of bio-ADM® predict blood pressure break down and blood vessel leakage resulting in edema AdrenOSS-2 Phase II trial shows that modulating the Adrenomedullin plasma level with the therapeutic antibody Adrecizumab demonstrates an improvement of survival in…
Read more

Novel data on sphingotec’s biomarkers for acute and critical care settings to be presented at AKI & CRRT 2020

Numerous talks and posters on sphingotec’s acute care biomarkers in the scientific program of the conference sphingotec to host symposium “Relevant Pathways, Novel Diagnostic and Therapeutic Approaches in Acute Organ Dysfunction”   Hennigsdorf, Germany, February 21, 2020 - SphingoTec GmbH (“sphingotec”) today announced that novel data on its acute care biomarkers Proenkephalin (penKid®) and Dipeptidyl Peptidase…
Read more

sphingotec’s biomarker penKid® shows best representation of true glomerular filtration rate and has utility in patients with severe burns two studies show

In-depth method comparison by Dutch group shows that sphingotec's proprietary kidney function biomarker penKid® is currently the most accurate surrogate marker for true glomerular filtration rate in patients with renal impairment Data by PRONOBURNS group show that penKid® accurately predicts acute kidney injury (AKI) in patients with burns, adding benefit on top of standard testing…
Read more